An observational study in Metastatic Breast Cancer, Circulating Tumor DNA and Gene Abnormality, sponsored by Hunan Cancer Hospital. Completed. Open to female participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2022-06-22.
Sponsored by Hunan Cancer Hospital · Observational
This is a retrospective, observational, multi-center clinical study of circulating tumor DNA (ctDNA) application in late-stage breast cancers.
This study aims to evaluate the feasibility of plasma ctDNA mutation spectrum and clonal spectrum in late-stage metastatic breast cancer patients. Meanwhile, this study tries to establish a model of ctDNA subtyping system to evaluate the molecular load of tumor, to evaluate the curative effect comprehensively and to detect the disease progression in advance. In addition, the investigators plan to explore the clonal evolution of ctDNA in patients with progressive disease (PD), and to monitor the changes of tumor heterogeneity from the molecular level, so as to provide reference for the analysis of drug sensitivity.
12,544 studies on the registry are indexed under Breast Neoplasms; 2,892 are open to participants now.
This study's enrollment of 223 is above the median of 184 across 2,642 observational studies indexed under Breast Neoplasms.
Browse Breast Neoplasms studies →Hunan Cancer Hospital is the lead sponsor of 54 studies on the registry; 28 are open to participants now.
Counted across the registry records on this site, refreshed daily.
This cohort study recruited consecutive patients with recent progression of metastatic TNBC after multiple lines of chemotherapy or of HR+ or HER2+ metastatic breast cancer after multiple lines of endocrine or targeted therapy.
Exclusion Criteria:
This cohort included patients with late-stage metastatic breast cancers and their disease progressed after at least two-line treatment.
Diagnostic Test: ctDNA testing
ctDNA testing was performed for late-stage metastatic breast cancer patients to trace their ctDNA abnormality.
ctDNA change index
The dynamic change of the frequency spectrum of ctDNA mutation in plasma.
Time frame: From the date of recruitment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 12 months.
No study locations are listed for this record.
Documents are hosted by the registry — open the source record to download them.
Plan to share: No
This study is completed, as verified in Jun 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Hunan Cancer Hospital